Kevin J Whitehead

Summary

Affiliation: University of Utah
Country: USA

Publications

  1. doi request reprint The pathogenetic features of cerebral cavernous malformations: a comprehensive review with therapeutic implications
    Khaled M Krisht
    Department of Neurosurgery, University of Utah, Salt Lake City, Utah 84132, USA
    Neurosurg Focus 29:E2. 2010
  2. pmc Arteriovenous malformations and other vascular malformation syndromes
    Kevin J Whitehead
    Molecular Medicine Program, University of Utah, Salt Lake City, Utah 84112, USA
    Cold Spring Harb Perspect Med 3:a006635. 2013
  3. pmc The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases
    Kevin J Whitehead
    Division of Cardiology, Department of Medicine, 30 North 1900 East, Room 4A100, University of Utah, Salt Lake City, Utah 84132, USA
    Nat Med 15:177-84. 2009
  4. pmc Mutations in 2 distinct genetic pathways result in cerebral cavernous malformations in mice
    Aubrey C Chan
    Molecular Medicine Program, University of Utah, Salt Lake City, Utah, USA
    J Clin Invest 121:1871-81. 2011
  5. pmc Nrf2 deficiency prevents reductive stress-induced hypertrophic cardiomyopathy
    Sankaranarayanan Kannan
    Cardiac Aging and Redox Signaling Laboratory, Rm 4A100, Division of Cardiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
    Cardiovasc Res 100:63-73. 2013
  6. pmc Recent insights into cerebral cavernous malformations: animal models of CCM and the human phenotype
    Aubrey C Chan
    Molecular Medicine Program, University of Utah, Salt Lake City, UT 84112, USA
    FEBS J 277:1076-83. 2010
  7. doi request reprint Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation
    Christopher C Gibson
    From the Program in Molecular Medicine C C G, W Z, C T D, J A B K, A C C, J L, A H G, K R T, K J W, D Y L, Department of Bioengineering C C G, Y T E S, Department of Medicine C C G, W Z, K R T, D Y L, Department of Human Genetics C T D, Department of Oncological Sciences A C C, D Y L, Division of Geriatrics, Department of Medicine A E W, A J D, L A L, Division of Nephrology and Hypertension, Department of Medicine Y T E S, Department of Pathology A H G, Division of Cardiology, and Department of Medicine K J W, D Y L, University of Utah, Salt Lake City, UT Recursion Pharmaceuticals, LLC, Salt Lake City, Minneapolis 55455
    Circulation 131:289-99. 2015
  8. pmc Mechanisms of vascular stability and the relationship to human disease
    Matthew C P Smith
    Molecular Medicine Program, Department of Oncological Sciences, University of Utah, Salt Lake City, Utah, USA
    Curr Opin Hematol 17:237-44. 2010
  9. pmc Endogenous endothelial cell signaling systems maintain vascular stability
    Nyall R London
    Department of Medicine, University of Utah, 15 N 2030 E, Salt Lake City, UT 84112 5330, USA
    Angiogenesis 12:149-58. 2009
  10. pmc Impact of mechanical unloading on microvasculature and associated central remodeling features of the failing human heart
    Stavros G Drakos
    Cardiovascular Department and Utah Artificial Heart Program, Intermountain Medical Center, Salt Lake City, Utah, USA
    J Am Coll Cardiol 56:382-91. 2010

Collaborators

Detail Information

Publications13

  1. doi request reprint The pathogenetic features of cerebral cavernous malformations: a comprehensive review with therapeutic implications
    Khaled M Krisht
    Department of Neurosurgery, University of Utah, Salt Lake City, Utah 84132, USA
    Neurosurg Focus 29:E2. 2010
    ..The remaining challenges to creating a more faithful CCM animal model as well as future clinical and research implications are reviewed...
  2. pmc Arteriovenous malformations and other vascular malformation syndromes
    Kevin J Whitehead
    Molecular Medicine Program, University of Utah, Salt Lake City, Utah 84112, USA
    Cold Spring Harb Perspect Med 3:a006635. 2013
    ..Here we review the vascular malformations and pathways involved in hereditary hemorrhagic telangiectasia, capillary malformation-arteriovenous malformation, cerebral cavernous malformations, and mucocutaneous venous malformations...
  3. pmc The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases
    Kevin J Whitehead
    Division of Cardiology, Department of Medicine, 30 North 1900 East, Room 4A100, University of Utah, Salt Lake City, Utah 84132, USA
    Nat Med 15:177-84. 2009
    ..These data offer the prospect for pharmacological treatment of a human vascular dysplasia with a widely available and safe drug...
  4. pmc Mutations in 2 distinct genetic pathways result in cerebral cavernous malformations in mice
    Aubrey C Chan
    Molecular Medicine Program, University of Utah, Salt Lake City, Utah, USA
    J Clin Invest 121:1871-81. 2011
    ..These results suggest that CCM may be more effectively treated by directing therapies based on the underlying genetic mutation rather than treating the condition as a single clinical entity...
  5. pmc Nrf2 deficiency prevents reductive stress-induced hypertrophic cardiomyopathy
    Sankaranarayanan Kannan
    Cardiac Aging and Redox Signaling Laboratory, Rm 4A100, Division of Cardiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
    Cardiovasc Res 100:63-73. 2013
    ....
  6. pmc Recent insights into cerebral cavernous malformations: animal models of CCM and the human phenotype
    Aubrey C Chan
    Molecular Medicine Program, University of Utah, Salt Lake City, UT 84112, USA
    FEBS J 277:1076-83. 2010
    ..Challenges and progress towards developing a faithful model of CCM biology are reviewed...
  7. doi request reprint Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation
    Christopher C Gibson
    From the Program in Molecular Medicine C C G, W Z, C T D, J A B K, A C C, J L, A H G, K R T, K J W, D Y L, Department of Bioengineering C C G, Y T E S, Department of Medicine C C G, W Z, K R T, D Y L, Department of Human Genetics C T D, Department of Oncological Sciences A C C, D Y L, Division of Geriatrics, Department of Medicine A E W, A J D, L A L, Division of Nephrology and Hypertension, Department of Medicine Y T E S, Department of Pathology A H G, Division of Cardiology, and Department of Medicine K J W, D Y L, University of Utah, Salt Lake City, UT Recursion Pharmaceuticals, LLC, Salt Lake City, Minneapolis 55455
    Circulation 131:289-99. 2015
    ..A subset of patients have a hereditary form of the disease due primarily to loss-of-function mutations in KRIT1, CCM2, or PDCD10. We sought to identify known drugs that could be repurposed to treat CCM...
  8. pmc Mechanisms of vascular stability and the relationship to human disease
    Matthew C P Smith
    Molecular Medicine Program, Department of Oncological Sciences, University of Utah, Salt Lake City, Utah, USA
    Curr Opin Hematol 17:237-44. 2010
    ..The genetic basis for a variety of vascular malformation syndromes have been described, with an increasing functional understanding of the associated genes...
  9. pmc Endogenous endothelial cell signaling systems maintain vascular stability
    Nyall R London
    Department of Medicine, University of Utah, 15 N 2030 E, Salt Lake City, UT 84112 5330, USA
    Angiogenesis 12:149-58. 2009
    ....
  10. pmc Impact of mechanical unloading on microvasculature and associated central remodeling features of the failing human heart
    Stavros G Drakos
    Cardiovascular Department and Utah Artificial Heart Program, Intermountain Medical Center, Salt Lake City, Utah, USA
    J Am Coll Cardiol 56:382-91. 2010
    ..This study investigates alterations in myocardial microvasculature, fibrosis, and hypertrophy before and after mechanical unloading of the failing human heart...
  11. pmc The netrin receptor UNC5B promotes angiogenesis in specific vascular beds
    Sutip Navankasattusas
    Program in Human Molecular Biology and Genetics, University of Utah, Salt Lake City, UT 84112, USA
    Development 135:659-67. 2008
    ....
  12. pmc Impaired transcriptional activity of Nrf2 in age-related myocardial oxidative stress is reversible by moderate exercise training
    Sellamuthu S Gounder
    Divisions of Cardiology and Pulmonary, Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, UT, USA
    PLoS ONE 7:e45697. 2012
    ..These observations suggest that enhancing Nrf2 function and endogenous cytoprotective mechanisms by MET, may combat age-induced ROS/RNS and protect the myocardium from oxidative stress diseases...
  13. pmc Evaluating strategies for the treatment of cerebral cavernous malformations
    Dean Y Li
    Department of Medicine, University of Utah, Salt Lake City, Utah 84112 5330, USA
    Stroke 41:S92-4. 2010
    ....